Cultures were fixed with absolute methanol for 20 minutes at −20°C or with phosphate-buffered 4% paraformaldehyde for 10 minutes at room temperature. Primary antibodies were reacted for 60 minutes at room temperature or overnight at 4°C. Primary antibodies used in this study were anti-pancytokeratin (pan-CK) antibody (422061; Nichirei, Tokyo, Japan), anti-GFAP antibody (N1506; DAKO, Glostrup, Denmark), anti-VWF antibody (A0082; DAKO), and anti–epidermal growth factor receptor (EGFR) antibody (ab2430; Abcam, Cambridge Science Park, UK) from rabbit; anti-vimentin antibody (sc7557; Santa Cruz Biotechnology, Santa Cruz, CA) and anti–hepatocyte growth factor receptor (c-Met) antibody (AF527; R&D Systems, Minneapolis, MN) from goat; anti–smooth muscle actin (SMA) antibody (asm-1; Labvision, Fremont, CA), anti-neurofilament antibody (01-20082; American Research Products, Belmont, MA), and anti-EGF antibody (MON 8001; MONOSAN, Uden, The Netherlands) of mouse monoclonal IgG, anti–cytokeratin 8 (CK-8) antibody (35βH11; DAKO) of monoclonal mouse IgM, and anti-CD34 antibody (Abcam) and anti–ZO-1 antibody (MAB1520; Chemicon, Temecula, CA) from rat.
Texas red- or fluorescein-conjugated secondary antibody (Vector Laboratories, Burlingame, CA) against the respective immunoglobulin of the primary antibody was reacted for 30 minutes at room temperature. Nuclear counterstaining was performed with 4′,6-diamidino-2-phenylindole (DAPI).
On some culture specimens, we performed double immunostaining for CK-8/vimentin, pan-CK/ZO-1, pan-CK/SMA, and SMA/vimentin. Primary antibodies were reacted together, and secondary antibodies were reacted separately in an appropriate order. Primary antibodies were omitted for the negative control. Samples were observed and photographed with a universal microscope (BioZero; Keyence, Osaka, Japan).